Last year, the Munich, Germany-headquartered contract development and manufacturing organisation (CDMO) acquired the Temmler Group extending its European operations. Now, almost a year to the day, Aenova is set to buy Haupt Pharma for an undisclosed price.
Aenova’s CEO, Heiner Hoppmann, said the two companies “complement each other very well” and the acquisition allows Aenova to focus on “forward-looking sectors in the pharmaceutical market.”
With the acquisition of Temmler, the company said its annual turnover has increased by over 60% to over €750m ($1.04bn). With the addition of Haupt, Aenova is once again adding a CMO it says will “achieve a strategic expansion of its portfolio.”
A recent Frost & Sullivan report on the contract manufacturing named Aenova as one of the top three players, controlling - along with Catalent and Patheon - a 23% of the current market. The report also spoke of CMOs both growing and surviving through consolidation.
For Aenova, the acquisition will bring a number of new services to its offerings, including sterile manufacturing and the production of special active ingredients, such as hormones, antibiotics and cytostatics.
Furthermore, Aenova will increase its network from eight to 21 sites with a number of production plants in Europe as well as a site in Japan, which will grant Aenova its first access into the Asian market.
For Haupt, being taken over by Aenova will allow continuous growth, increasing “competitiveness in a challenging market,” according to Haupt Chairman Otto Prange.
Aenova was unable to offer any further details when contacted by Outsourcing-pharma.com.